Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Specific and efficient cleavage of fusion proteins by recombinant plum pox virus NIa protease

Nuoyan Zheng a,c, José de Jesús Pérez b, Zhonghui Zhang c, Elvira Domínguez b, Juan Antonio Garcia b, Qi Xie a,c,*

a State Key Laboratory for Biocontrol, Sun Yat-sen (Zhongshan) University, 135 Xinggang Road W, Guangzhou 510275, China
b Centro Nacional de Biotecnología-CSIC, Campus Universidad Autónoma de Madrid, 28049 Madrid, Spain
c State Key Laboratory of Plant Genomics, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Datun Road, Beijing 100101, China

Received 8 August 2007, and in revised form 26 September 2007
Available online 22 October 2007

Abstract

Site-specific proteases are the most popular kind of enzymes for removing the fusion tags from fused target proteins. Nuclear inclusion protein a (NIa) proteases obtained from the family Potyviridae have become promising due to their high activities and stringencies of sequences recognition. NIa proteases from tobacco etch virus (TEV) and tomato vein mottling virus (TVMV) have been shown to process recombinant proteins successfully in vitro. In this report, recombinant PPV (plum pox virus) NIa protease was employed to process fusion proteins with artificial cleavage site in vitro. Characteristics such as catalytic ability and affecting factors (salt, temperature, protease inhibitors, detergents, and denaturing reagents) were investigated. Recombinant PPV NIa protease expressed and purified from Escherichia coli demonstrated efficient and specific processing of recombinant GFP and SARS-CoV nucleocapsid protein, with site F (NVVVHQ A) for PPV NIa protease artificially inserted between the fusion tags and the target proteins. Its catalytic capability is similar to those of TVMV and TEV NIa protease. Recombinant PPV NIa protease reached its maximal proteolytic activity at approximately 30 °C. Salt concentration and only one of the tested protease inhibitors had minor influences on the proteolytic activity of PPV NIa protease. Recombinant PPV NIa protease was resistant to self-lysis for at least five days.

Keywords: PPV NIa protease; Fusion protein; Fusion tag cleavage

The application of recombinant proteins is well-accepted approach for producing useful protein products such as industrial material and therapeutic proteins. Fusion tags have been very helpful, not only for the purpose of detection and purification of target proteins, but also for the purpose of improving the solubility of target proteins in different bioreactors (prokaryotic, yeast, animal, plant, and virus systems) [1–4]. Examples of such tags are hexahistidine [5], streptavidin [6], glutathione-S-transferase (GST)1 [7], and maltose-binding protein (MBP) [8], Flag [9], tandem affinity purification (TAP) [10], thioredoxin (Trx) [11]. However, the fusion tags may interfere with the structures and functions of the target proteins. It is preferable that fusion tags can be removed after purification and several strategies have been applied for this task [4]. Cleaving at a specifically recognized sequence that are hexahistidine [5], streptavidin [6], glutathione-S-transferase (GST)1 [7], and maltose-binding protein (MBP) [8], Flag [9], tandem affinity purification (TAP) [10], thioredoxin (Trx) [11]. However, the fusion tags may interfere with the structures and functions of the target proteins. It is preferable that fusion tags can be removed after purification and several strategies have been applied for this task [4]. Cleaving at a specifically recognized sequence that

1 Abbreviations used: NIa, nuclear inclusion protein a; TEV, tobacco etch virus; TVMV, tomato vein mottling virus; GST, glutathione-S-transferase; MBP, maltose-binding protein; TAP, tandem affinity purification; Trx, thioredoxin; IPTG, isopropyl-β-D-thiogalactopyranoside; OCI and OCII, oryzacystatins I and II; CCII, corn cystatin II; HSA, human stefin A; CP, capsid protein.
has been inserted between the tag and the target protein by a specific protease is a convenient way to eliminate the fusion tag. The commonly used proteases include factor Xa, thrombin, enterokinase, and tobacco etch virus (TEV) Nl protease, although each protease has its own advantages and disadvantages. Factor Xa can recognize and cleave at the sequence of Ile-Glu/Asp-Gly-Arg, which naturally converts prothrombin to thrombin [12]. However, under certain circumstances, factor Xa may cleave at non-specific sequences besides the predicted sites [13,14]. Additionally, factor Xa may be disabled by adjacent hydrophobic sequences flanked on the C-terminal side of the potential site [15]. The optimal cleavage sites for thrombin have the following structures: (a) P4-P3-Pro-Arg^P1'-P2', where P3 and P4 are hydrophobic acid and P1', P2' are nonacidic amino acids; (b) P2-Arg^P1', where P2 or P1' are Gly [16]. However, Chang et al. found out that thrombin can cleave at the lysine residues in the sequences Met-Lys^Ser-Arg-Asn-Leu, Arg-Cys-Lys^Pro-Val-Asn, and Ser-Ser-Lys^Tyr-Pro-Asn in performic acid-oxidized ribonuclease when studied the action of thrombin on 30 polypeptide hormones [16]. Due to its high stringency of sequence recognition, TEV Nl protease has been frequently used in the recent time. The specificity of TEV Nl protease has been well investigated [17–20]. The preferred site for TEV Nl protease is considered to be site F (P6)E (P5)N (P4)V (P3)V (P2)H (P1)Q, where P3 and P4 are hydrophobic acid and P1, P2 can be any amino acid except Pro [21,22]. Recombinant TEV Nl protease has been used for removing several fusion tags in vitro, processing on artificial site F efficiently [23–26]. However, the wild-type TEV Nl protease may degrade into a truncated form with severely diminished enzymatic activity [27], which temporarily limited its range of application. Alternatively, TEV Nl protease mutants S219V or S219D, which temporarily limited its range of application. Nevertheless, TVMV Nl protease did not show self-degradation that was detected in wild-type TEV Nl protease [29]. It has been reported that PPV Nl protease recognized and processed natural and artificial site F efficiently within the E. coli expression system [37,38]. Recombinant PPV Nl protease purified from E. coli can cleave at canonical cleavage site F (Nl-CP junction) in vitro [39]. These experiments suggested that PPV Nl protease has potential for removing fusion tags in vitro when site F (P6)N (P5)V (P4)V (P3)V (P2)H (P1)Q^P1'A for PPV Nl protease is inserted between fusion tags and target proteins.

This study mainly focused on the efficient and specific processing of fusion proteins by recombinant PPV Nl protease in vitro. A detailed evaluation of the efficiency, stability, and affecting factors of the purified protease was performed. We used tagged versions of GFP and SARS-coronavirus nucleocapsid protein as substrates, with the cleavage site F for PPV Nl protease inserted between fusion tags and target proteins. Both the protease and the fused target proteins were expressed in the E. coli cells and purified by Ni-NTA affinity chromatography.

Material and methods

Construction of expression vectors pET-P, pET-sN, and pET-sG

The potyvirus Nl protein contains the following two domains: the VPg domain at the N-terminus and the Nl protease domain at the C-terminus. The DNA sequence coding for the protease domain was amplified by PCR using plasmid pGGNl as template. Plasmid pGGNl contains the partial cDNA sequence of plum pox virus (Rankovic strain). Recognition site of the restriction endonuclease SacI was added to the 5' end of primer 1 (5'-CAgagcttGAAGATATCCTAGTTCCAGGG-3') and HindIII site was added to the 5' end of primer 2 (5'-CtagacctGTAGGTGTAACAAATTTCC-3'). This fragment was digested with SacI and HindIII, and subsequently inserted into the SacI–HindIII-treated pET-32a
(+)(Novagen) vector. The consequential plasmid was referred to as pET-P, which contained the N1a protease domain coding sequence.

A BAC clone containing the cDNA of SARS-CoV (Urbani strain) was used to amplify the coding sequence for SARS-CoV nucleocapsid (N) protein by PCR. Primer 3 (5′-gcagcachegcacATGGTCTGATAATGGACC-3′) and primer 4 (5′-ATacgcgtTTATGCCTGAGTTGAATC-3′) were used. Nucleotides gcag and gtcgac in primer 3 represent the recognition sequences for the restriction enzymes Sphi and SalI, respectively, while the nucleotide acgcgt in primer 4 is an NcoI recognition site. The PCR product was subcloned into pGEM-T easy vector (Promega). This plasmid was referred to as pGEM-T-N. Oligodeoxynucleotides containing the site F for PPV N1a protease sequence (5′-CGGTACCAACGTTGTTGTGCACCAAGCTGACGAACTGCAGCCATGGC-3′) and (5′-TCAGTCCATGCTGACAGCTGGATGCCAAC-3′) were synthesized and annealed, and subsequently inserted between the Sphi–SalI digested pGEM-T-N vector, thereby resulting in a new plasmid pGEM-T-sN. The KpnI–SalI fragment obtained from pGEM-T-sN that contained the coding sequence for N protein was inserted into the KpnI–SalI-digested pET-32a (+) vector, thereby yielding the plasmid pET-sN. For the construction of pET-sG, primer 5 (5′-ACCATGGAAGCTCAGGGCTGGTAAGGGAGAAGAACTT-3′) and primer 6 (5′-GGactgtgagctcTTATTTGTATAGTTCATCCAT-3′) were used to perform PCR amplification of the GFP gene obtained from pGFP-2 plasmid, which contains the GFP gene. This amplified fragment was digested with NcoI and SpeI and substituted in plasmid pET-sN for the NcoI–SpeI fragment that contained the coding sequence for N protein.

All these constructs were confirmed by restriction enzymes mapping and sequencing. The final constructs

![Fig. 1. Amino acid sequences alignment for TEV, TVMV, and PPV N1a proteins (both the VPg and the N1a protease domains). The alignment was performed using the software DNAMAN. The catalytic triad His46–Asp81–Cys151 occurs at the same amino acid positions of the PPV, TEV, and TVMV N1a protease domain (indicated by ⬤).](image-url)
Expression in *E. coli* and purification of recombinant protease and substrates

The *E. coli* BL21AI cells carrying different constructs were grown overnight in LB medium supplemented with 100 µg/mL ampicillin at 37 °C. The overnight culture was diluted with LB to generate a start absorbance of 0.1 and was subsequently shaken at 18 °C. An hour later, isopropyl-β-D-thiogalactopyranoside (IPTG) was added with a final concentration of 0.25 mM, and the incubation was prolonged for an additional 12–16 h. Under these conditions, high expression levels of protease and substrates were observed. The cells were harvested by centrifugation, washed extensively with PBS (137 mM NaCl, 2 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4), and frozen at −20 °C. The cell pellets were resuspended and homogenized in ice-cold lysis buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8.0) containing protease inhibitors (1 mM PMSF, 1 mg/mL benzamidine, 2 µg/mL aprotinin, and 1 µM pepstatin A), then disrupted by French Press. The homogenates were centrifuged at 12,000 rpm (CR 22G, Himac) at 4 °C for 45 min to remove the cell debris. The 6× His tag-fused proteins were subsequently purified with Ni-NTA agarose column (Cat. No. 30210, QIAGEN) according to the manufacturers instructions. The pure 6× His His-tagged proteins were eluted with a step-wise imidazole concentration gradient (100–500 mM). The eluted recombinant proteins were further concentrated and desalted by using an Amicon Ultra-15 membrane (Millipore). Purified PPV NIa protease was resuspended in 15% glycerol till a concentration of 1 mg/mL was achieved and stored in aliquots at −80 °C. The substrates were resuspended in PBS and stored in aliquots at −80 °C. Protein concentrations were estimated by Bradford method and compared with the standard concentration of BSA (Bradford Protein Assay kit, Beyontime, China).

**PPV NIa protease processing of fusion proteins**

One microgram of the recombinant PPV NIa protease was incubated with varied amounts of sG or sN at 30 °C in the reaction buffer. The reaction was terminated with 4× SDS–PAGE sample buffer and heated at 95 °C for 10 min. The samples were analyzed by SDS–PAGE and stained with Coomassie brilliant blue R-250 (CBB R-250).

**Effects of temperature, salt concentration, protease inhibitors, and chemical reagents on recombinant PPV NIa proteases proteolytic activity**

In order to analyze the effect of temperature on the enzymatic activity of recombinant PPV NIa protease, 50 µg of sG and 1 µg of recombinant PPV NIa protease were mixed in the reaction buffer, and incubated at 4, 20, 30, and 40 °C for up to 10 h. Additionally, the effect of salt concentration on the enzymatic activity of PPV NIa protease was examined. Fifty micrograms of sG and 1 µg recombinant PPV NIa protease were incubated in the reaction buffer mentioned above containing additional NaCl at increasing concentrations (50, 100, 200, 300, and 500 mM) at 30 °C for up to 6 h.

In order to assess the effect of protease inhibitors on the enzymatic activity of PPV NIa protease, 50 µg of sG substrate and 1 µg recombinant PPV NIa protease were incubated in the reaction buffer containing different commercial inhibitors of serine-, aspartic-, cysteine-, and metallo-proteases at 30 °C for 2 h. Those protease inhibitors are 1 mM PMSF (serine- and metallo-protease inhibitors), 5 mM benzamidine (serine-protease inhibitor), 0.1 mM pepstatin A (aspartic protease inhibitors), 200 µg/mL aprotinin–dihydrochloride (serine proteases and esterase inhibitor), 1 mM leupeptin (cysteine- and serine-protease inhibitor), 1 mM antipain (cysteine- and serine-protease inhibitor), and 50 mM EDTA-Na2 (metallo proteases inhibitor). The effect of some denaturing reagents or detergents on the activity of PPV NIa protease was also analyzed. Eighty-five micrograms of sG substrate and 1 µg of recombinant PPV NIa protease were incubated at 30 °C for 3 h in the reaction mixture supplemented with different concentrations of urea, Triton X-100, and SDS. In all cases, the samples were analyzed by using SDS–PAGE and Coo-
massie blue staining as described above. Three independent experiments were conducted to obtain the numerical estimates of the fraction of the cleaved substrates at each time point. The Coomassie-stained gels were scanned with a Uniscan C1080 scanner (THUNIS), and the pixel densities of the bands were quantified by using the ImageQuant TL v2005 software (GE health). The average values and the standard errors were generated by Microsoft Excel. The kinetic parameters of recombinant PPV NIa protease were estimated by Origin 7.5 software (OriginLab).

Self-inactivation test of PPV NIa protease

One microgram of the recombinant PPV NIa protease was incubated in the reaction buffer at 4 and 20 °C for up to 120 h. Aliquots were collected at different incubation times and analyzed by SDS–PAGE and Coomassie blue staining as explained above.

Results

Expression in E. coli and purification of recombinant PPV NIa protease and substrates

The NIa protease domain in the PPV NIa protein was selected for the purpose of evaluating its enzymatic activity. The cDNA coding region for the protease domain was cloned into pET-32a (+) expression vector, thereby resulting in the formation of pET-P vector (Fig. 2a). pET-32a (+) expression vector provides Trx tag, 6His tag, and S tag at the amino terminus and 6His tag at the carboxyl terminus for recombinant PPV NIa protease. The bacteria harboring this expression plasmid were induced with IPTG at a temperature of 18 °C and produced recombinant PPV NIa protease of 47 kDa (Fig. 2c, indicated as rProtease). No extra or degraded bands were observed for recombinant PPV NIa protease. Most of the recombinant PPV NIa protease was eluted by 250–500 mM imidazole. The recombinant PPV NIa protease was largely soluble and purified by using nickel affinity chromatography. Approximately 20 mg soluble recombinant PPV NIa protease was obtained from 1 liter of bacteria culture.

Fused versions of GFP and SARS-CoV N (indicated as sG and sN) protein were expressed in E. coli as substrates for recombinant PPV NIa protease. A linker containing the most efficient recognition site F (NVVVHQ.A) for PPV NIa protease was inserted between the N-terminal fusion tags and the C-terminal GFP or SARS-CoV N protein (Fig. 2b). Since the amino acids adjacent to the recognition site may interfere with the cleaving ability of the protease [34], the two original amino acids Asp, Glu behind Ala were incorporated in the linker to optimizing the cleavage efficiency. S tag, Trx tag, and 6His tag in front of GFP or SARS-CoV N protein can be used to facilitate purification. Soluble 45 kDa sG protein and 64 kDa sN protein accumulated to high levels in the transformed bacteria and were easily purified by nickel affinity chromatography. The yields of purified sG and sN proteins from E. coli were 80 and 30 mg/L, respectively (Fig. 2d and e).

Primary test of NIa protease activity on a PPV NIb-CP substrate

In order to test whether the native NIb-CP junction (site F) could be recognized by the recombinant PPV NIa protease and estimate the proteolysis efficiency, NIb-CP protein was translated and 35S-labeled with a coupled in vitro transcription–translation system. Subsequently, the translated mixtures were treated with the purified PPV NIa pro-
tease. Most of the translated products were processed by 0.5 μg of recombinant PPV NIa protease at 20 or 30 °C within 5 min, resulting in two bands of 54.5 and 36.5 kDa. These two bands are corresponding to the sizes of PPV NIb and capsid protein translated from plasmid template, respectively (Fig. 3). This indicates that the recombinant PPV NIa protease produced and purified from E. coli functions well for the canonical PPV NIb-CP junction in vitro. Furthermore, NIb-CP protein of PPV expressed from E. coli was well-processed by purified recombinant PPV NIa protease (data not shown).

**In vitro proteolytic assay for NIa protease processing specific fusion proteins**

To investigate the capability of PPV NIa protease to process fusion proteins in vitro, we chose recombinant GFP (sG) and SARS-CoV Nucleocapsid protein (sN) as substrates. The GFP protein expressed and purified from E. coli is stable, well-characterized and widely used; however, therapeutic proteins are more often complex and vulnerable with regard to their structures and functions. In this test, substrate sG or sN (50–100 μg) was incubated in the reaction buffer in the presence of 1 μg of PPV NIa protease. More than 80% of the substrate (50 μg of sG or sN) could be cleaved efficiently and specifically in vitro by 1 μg recombinant PPV NIa protease at 30 °C within 2 h, yielding a free GFP protein (28 kDa) or a free SARS-CoV N protein (47 kDa) (Fig. 4 sG-lane 2, sN-lane 2). Furthermore, more than 95% of substrate (100 μg of sG or sN) could be cleaved at 30 °C after 10 h and no by-products occurred (Fig. 4 sG-lane 3, sN-lane 3). No significant difference of catalytic efficiency was observed in the processing of two substrates sG and sN.

**Effects of temperature, salt concentration, protease inhibitors, and chemical reagents on the enzymatic activity of recombinant PPV NIa protease**

Fifty micrograms of sG and 1 μg of recombinant PPV NIa protease were incubated at 4, 20, 30, and 40 °C to estimate the effect of temperature on the protease kinetics. The result showed the optimal temperature for recombinant PPV NIa protease is approximately 30 °C. However, 1 μg of recombinant PPV NIa protease exhibited adequate activity for processing 50 μg of the substrate at 20 °C in 10 h. Considerable activity was observed at 4 °C, though activity was severely diminished at 40 °C (Fig. 5a). At 40 °C, degradation of GFP after cleavage was observed when the cleaved products were analyzed by SDS-PAGE; hence, high temperature is not recommended for the cleavage by PPV NIa protease. The initial velocity of recombinant PPV NIa protease at 30 °C were 1.21-fold and 1.79-fold of those at 4 and 40 °C, respectively.

Salt concentration was another common variable affecting the activity of the protease. The dependence of recombinant PPV NIa protease on salt is much less than that on temperature (Fig. 5b). Even in the presence of 500 mM NaCl, 40% of 50 μg sG was cleaved by 1 μg recombinant PPV NIa protease at 30 °C within 30 min; more than 60% substrate was specifically processed after 6 h. Monovalent ion strength, up to 200 mM, played a minor role on the performance of recombinant PPV NIa protease.

The naturally accruing proteases can be grouped into four classes according to the prominent functional residue at the active site: Ser, Cys, Asp, and metal [36,41]. NIa proteases from TEV, TVMV, and PPV are similar to trypsin-like serine proteases but adopt unconventional catalytic triad in which Cys replaces Ser [42]. There are many reagents that can inhibit the protease function irreversibly or reversibly. To test whether commonly used protease inhibitors can affect the behavior of recombinant PPV NIa protease, recombinant PPV NIa protease (1 μg) and the substrate sG (50 μg) were incubated at 30 °C for 2 h, supplemented with different protease inhibitors. These protease inhibitors were used at high concentrations (even up to 100 times of their usual dosages). Only 1 mM PMSF had an effect, albeit slight, on the protease activity; other tested protease inhibitors (benzamidine, pepstatin A, apro-
tinin, leupeptin, antipain, and EDTA) had no effect on recombinant PPV NIa protease (Fig. 5c). Previous report showed human cystatin C affected PPV NIa protease activity in certain level when used at high concentration of 400 \mu g/ml [43]. In another way, the purified PPV NIa protease was not inhibited by other cystatins, such as oryza-cystatins I and II (OCI and OCII), corn cystatin II (CCII), human stefin A (HSA), the domain 8 of tomato multicystatin (TMC-8) and a large 24 kDa tomato cystatin (LTCyst), when used at a molar ratio of 1:40 (NIa:cystatin) [39]. According to the detail manual of Devid S. Waugh laboratory (http://mcl1.ncifcrf.gov/waugh_research.html), TEV protease was not affected by PMSF (1 mM), AEBSF (1 mM), TLCK (1 mM), Bestatin (1 mg/ml), peptatin A (1 mM), EDTA (1 mM) and E-64 (3 mg/ml), and a commercial “complete” protease inhibitor cocktail (Roche), which is frequently used to inhibit serine-, cysteine-, and metallo- proteases, as well as calpains, of bacterial, mammalian, yeast, and plant cell extracts. However, zwitter-ionic detergent (APO-10, DDMAB, DDMG, FC-12, HECAMEG, LDAO, OG, and ZW 3–12) notably inhibited the proteolytic activity of rTEV [44]. We chose two common detergents, SDS (also working as a denaturing reagent) and Triton X-100, to test their effects on the activity of PPV NIa protease. As we can see from Fig. 5d, recombinant PPV NIa protease was very sensitive to SDS, losing most of its proteolytic activity in the presence of 0.05% SDS, whereas recombinant PPV NIa protease was quite tolerant to Triton X-100 (up to 2%). Another denaturing reagent, urea, had almost no affect on the performance of recombinant PPV NIa protease when used at a final concentration of 1 M. About 30% activity of recombinant PPV NIa protease was blocked by 2 M urea.

### Stability assay of PPV NIa protease

Wild-type TEV NIa protease is very prone to autolysis, thereby resulting in a truncated protein with poor cleavage activity [27,28]. PPV NIa protease was homologous to TEV NIa protease; thus, the stability of recombinant PPV NIa protease was also analyzed. No self-degradation of recombinant PPV NIa proteases was observed during incubation for up to 120 h at 4 °C or 20 °C (Fig. 6). The autolysis of TEV NIa protease occurs between Met218 and Ser219 in the GHKVFM sequence. This sequence can be aligned with the corresponding sequences SFTLVED and SLQKRD in autolysis-resistant TVMV and PPV NIa proteases, respectively. TVMV NIa protease and PPV NIa protease both encode D219, while TEV

---

**Fig. 5.** Impacts of temperature, ionic strength, and protease inhibitors on the enzymatic activity of recombinant PPV NIa protease. (a) Effect of temperature on the enzymatic activity of recombinant PPV NIa protease. Fifty micrograms of substrate sG and 1 \mu g of protease were incubated at different temperatures (4, 20, 30, and 40 °C) with a final substrate concentration of 1 \mu g/ml in the reaction system. The corresponding aliquots were collected and analyzed at different time points (5, 20, 30, 60, 120, 240, and 600 min). (b) Effect of salt on the enzymatic activity of recombinant PPV NIa protease. Fifty micrograms of substrate sG and 1 \mu g of protease were incubated at 30 °C in the reaction buffer containing additional NaCl at increasing concentration (0, 50, 100, 200, 300, and 500 mM). The aliquots were collected and analyzed at each time point (5, 30, 60, 120, 240, and 360 min). (c) Effect of protease inhibitors on the enzymatic activity of recombinant PPV NIa protease. Fifty micrograms of substrate sG and 1 \mu g of protease were incubated at 30 °C in the reaction buffer containing additional NaCl at increasing concentration (0, 50, 100, 200, 300, and 500 mM). The aliquots were collected and analyzed at each time point (5, 30, 60, 120, 240, and 360 min). (d) Effect of protease inhibitors on the enzymatic activity of recombinant PPV NIa protease. Fifty micrograms of substrate sG and 1 \mu g of protease were included in a 50 \mu l reaction system at 30 °C for 2 h in the presence of the indicated protease inhibitors. PMSF, phenylmethylsulfonyl fluoride; Benz, benzamidine; Pep. A, peptatin A; Apro, aprotinin; Leu, leupeptin; Anti, antipain-dihydrochloride; EDTA, ethylene diamine tetraacetic acid. The reaction mixture in the absence of protease inhibitors was used as the positive control. (d) Effect of detergents and denaturing reagents on the enzymatic activity of recombinant PPV NIa protease. Eighty micrograms of substrate sG and 1 \mu g of protease were included in a 50 \mu l reaction system at 30 °C for 3 h in the presence of the indicated reagents. The concentration units of urea, Triton X-100, and SDS were mol/L, % (v/v), % (w/v), respectively. The reaction mixture without additional reagents was used as the positive control and uncleaved substrate sG was used as negative control.
NIa protease encodes S219 (Fig. 1, underlined region). Similarly, S219D mutant of TEV NIa protease was 10-fold more resistant to auto-inactivation than wild-type TEV NIa protease [28].

Discussion

The large proportion of recombinant PPV NIa protease produced in *E. coli* BL21AI cells is soluble. This suggested the fusion tags (Trx tag, 6× His tag, and S tag) in front of PPV NIa protease favored the soluble status of recombinant PPV NIa protease. However, it was reported that only MBP, but not GST or Trx, can improve the solubility of recombinant TEV NIa protease [45]. For achieving soluble product, recombinant TVMV NIa protease was also expressed as MBP-TVMV NIa fusion protein [29]. On another aspect, recombinant PPV NIa protease was resistant to auto-degradation for at least 5 days at 20 °C, which has not been shown before and it is a crucial factor for prolonged cleavage activity. Recombinant TVMV NIa protease and mutant TEV NIa protease S219V were reported to remain stable during overnight incubation, but no prolonged assay was performed [29]. The recombinant PPV NIa proteases mentioned in this study was designed to be fused with 6× His tags, therefore, the protease can be easily removed from reaction mixture by passing through a nickel affinity column after cleavage. This property is similar as the commercial TEV NIa protease (AcTEV™, Invitrogen).

Another concern is the purity of the protease. NIa proteases expressed as recombinant proteins in *E. coli* yield as highly pure product after purification through affinity chromatography, compared with animal-derived factor Xa and thrombin, which may have contamination of plasmid [46–48].

Many fusion tags are now available for optimizing the expression and purification of target proteins; therefore proteases are demanded to be highly specific towards the expected cleavage sites. We found that recombinant PPV NIa protease was extremely specific toward the cleavage sequence; no processing of Trx tag, hexahistidine tag, S tag, GST tag (data not shown) and MBP tag (data not shown) was observed, even during overnight cleavage. We chose the naturally preferred site F [32,37,38] as the recognition sequence in fused substrates for recombinant PPV NIa protease. Two different substrates (sG and sN) with insertion of site F were both cleaved efficiently by recombinant PPV NIa protease, indicating the interaction between protease and substrate was highly specific and efficient in both cases. The corresponding sites F for TEV, TVMV, and PPV were E N L Y F Q▼S, E T V R F Q▼S, and N V V V H Q▼A, all adopting a conserved residue Gln in the P1 position [21,29,37]. The specificity of PPV NIa protease has been studied, mainly illustrating with anomalous proteolytic processing caused by mutated proteases or mutated substrates [31,38,49,50], thus a further analysis of the specificity and efficiency of PPV NIa protease-substrate complex by crystal structural is required. Although most studies about the cleavage determinant factors for NIa protease were performed with TEV and TVMV [20,21,33,51], the high conserved amino acid sequence and function among PPV, TEV, and TVMV NIa protease indicate the recognition mechanism of TEV and TVMV NIa protease may also fit for PPV NIa protease [52]. The crystal structures of TEV and TVMV NIa protease suggested that the S4 and S3 pockets are primarily responsible for their different sequence specificities and that the residues in the P3 and P4 positions of the cleavage sites are the most important specificity discriminators [21].

The fact that recombinant PPV NIa protease maintained high activities in wide range of temperature (4–30 °C), high salt strength (even in 300 mM NaCl) and in the presence of protease inhibitors rendered it suitable for specific processing of labile proteins that demand such requirements. In addition, denaturing reagents and detergents were often required in the purification of insoluble or organellar proteins. The recombinant PPV NIa protease was sensitive to 0.05% SDS, but it was tolerant to both 2% Triton X-100 and 1 M urea. Comparatively, a commercial protease factor Xa (Cat. No. 69036-3, Novagen) is sensitive to urea, SDS, and high salt concentration (above 250 mM). The enzymatic ability of recombinant PPV NIa protease is similar to that reported by TVMV and TEV NIa protease with respect to molar ratio of protease and substrate [29,53]. All the data indicates recombinant PPV NIa protease is a promising universal tool for fusion tags removal.

Proteins which are capable of *in vivo*-cleavage (for example, the intein protein from yeast) may be advanced in protein expression and purification [54]. Intracellular self-cleavage by TEV NIa protease on fusion protein MBP-TEVP-rsTEV-GFP-His₆ (rsTEV: recognition site for TEV NIa protease) resulted in native and soluble EGFP protein [55]. When a fusion protein containing site F and the PPV NIa protease were driven by two compatible plasmids and expressed simultaneously within *E. coli*, the PPV NIa protease could process on site F correctly *in vivo* [56]. We can propose that two possible interacted-proteins and the PPV NIa protease may be fused together, separated by two cleavage sites, thereby the whole polypeptide can be expressed from one single vector. In this way, the protease component in the polypeptide is likely to perform self-cleavage *in vivo*, which will facilitate the analysis of the interaction between the two proteins *in vivo*. 
Acknowledgments

This work was supported by Grants from the European Commission Sixth Framework Program (No. SP22-CT-2004-511060) and the National Natural Science Foundation of China (No. 30325030/30530400). We thank Dr. Luis Enjuanes from CNB-CSIC Spain for kindly providing the SARS-CoV cDNA clone.

References

[1] S. Chatterjee, J. Schoepe, S. Lohmer, D. Schomburg, High level expression and single-step purification of hexahistidine-tagged 2,2-dihydroxyisocaproate dehydrogenase making use of a versatile expression vector set, Protein Expr. Purif. 39 (2005) 137–143.

[2] S. Campbrui, M. Bruguer, F. Canalias, Purification of recombinant histidine-tag streptolysin O using immobilized metal affinity expanded bed adsorption (IMA-EBA), Int. J. Biol. Macromol. 38 (2006) 134–139.

[3] F. Bernaudat, L. Bulow, Combined hydrophobic-metal binding fusion tags for applications in aqueous two-phase partitioning, Protein Expr. Purif. 46 (2006) 438–445.

[4] J. Nilsson, S. Stahl, J. Lundeberg, M. Uhlen, P.A. Nygren, Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins, Protein Expr. Purif. 11 (1997) 1–16.

[5] S.K. Sharma, D.B. Evans, A.F. Vosters, T.J. McQuade, W.G. Tarpley, Metal affinity chromatography of recombinant HIV-1 reverse transcriptase containing a human renin cleavable metal binding domain, Biotechnol. Appl. Biochem. 14 (1991) 69–81.

[6] C.F. Ford, I. Suominen, C.E. Glatz, Fusion tails for the recovery and purification of recombinant proteins, Protein Expr. Purif. 2 (1991) 95–107.

[7] D.B. Smith, K.S. Johnson, Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase, Gene 67 (1988) 31–40.

[8] C. di Guan, P. Li, P.D. Riggs, H. Inouye, Vectors that facilitate the cloning and purification of recombinant proteins, J. Biochem. Biophys. Methods 24 (2001) 218–229.

[9] E. Benarie, J.F. Griffith, N. Chinn, E. Lavallie, G. Buchan, The cloning expression and purification of cervine interleukin 2, Cytokine 8 (1996) 603–612.

[10] R. Radcliffe, Y. Nemerson, Mechanism of activation of bovine factor VII. Products of cleavage by factor Xa, J. Biol. Chem. 251 (1976) 4749–4802.

[11] T. Kupke, S. Stevanovic, B. Ottenwalder, J.W. Metzger, G. Jung, F. Gotz, Purification and characterization of EpiA, the peptide substrate for post-translational modifications involved in epidermin biosynthesis, FEMS Microbiol. Lett. 112 (1993) 43–48.

[12] A.P. Doskeland, A. Martinez, P.M. Knappskog, T. Flattmark, Phosphorylation of recombinant human phenylalanine hydroxylase: effect on catalytic activity substrate activation and protection against non-specific cleavage of the fusion protein by restriction protease, Biochem. J. 313 (Pt 2) (1996) 409–414.

[13] M. He, L. Jin, B. Austen, Specificity of factor Xa in the cleavage of fusion proteins, J. Protein Chem. 12 (1993) 1–5.

[14] J.Y. Chang, Thrombin specificity. Requirement for apolar amino acids adjacent to the thrombin cleavage site of polypeptide substrate, Eur. J. Biochem. 151 (1985) 217–224.

[15] W.G. Dougherty, J.C. Carrington, S.M. Cary, T.D. Parks, Biochemical and mutational analysis of a plant virus polyprotein cleavage site, EMBO J. 7 (1988) 1281–1287.

[16] J.C. Carrington, R. Haldeman, V.V. Dolja, M.A. Restrepo-Hartwig, Internal cleavage and trans-proteolytic activities of the Vpg-protease (NIa) of tobacco etch potyvirus in vivo, J. Virol. 67 (1993) 6995–7000.

[17] M.C. Schaad, R. Haldeman-Cahill, S. Cronin, J.C. Carrington, Analysis of the Vpg-protease (NIa) encoded by tobacco etch potyvirus: effects of mutations on subcellular transport, proteolytic processing and genome amplification, J. Virol. 70 (1996) 7039–7048.

[18] J. Phan, A. Zdanov, A.G. Evdokimov, J.E. Tropea, H.K. Peters 3rd, R.B. Kapust, M. Li, A. Wlodawer, D.S. Waugh, Structural basis for the substrate specificity of tobacco etch virus protease, J. Biol. Chem. 277 (2002) 50564–50572.

[19] J. Tozser, J.E. Tropea, S. Cherry, P. Bagossi, T.D. Copeland, A. Wlodawer, D.S. Waugh, Comparison of the substrate specificity of two potyvirus proteases, FEBS J. 272 (2005) 514–523.

[20] W.G. Dougherty, S.M. Cary, T.D. Parks, Molecular genetic analysis of a plant virus polyprotein cleavage site: a model, Virology 171 (1989) 356–364.

[21] L.D. Cabrita, W. Dai, S.P. Bottomley, A family of E. coli expression vectors for laboratory scale and high throughput soluble protein production, BMC Biotechnol. 6 (2006) 12.

[22] V. Rubio, Y. Shen, Y. Saijo, Y. Liu, G. Guzmarioli, S.P. Dinesh-Kumar, X.W. Deng, An alternative tandem affinity purification strategy applied to Arabidopsis protein complex isolation, Plant J. 41 (2005) 767–778.

[23] S. Braud, M. Moutiez, P. Belin, N. Abello, P. Drevet, S. Zinn-Justin, M. Courcon, C. Masson, J. Dassa, J.B. Charbonnier, J.C. Boulain, A. Menez, R. Genet, M. Gondry, Dual expression system suitable for high-throughput fluorescence-based screening and production of soluble proteins, J. Proteome Res. 4 (2005) 2137–2147.

[24] T.D. Parks, K.K. Leuther, E.D. Howard, S.A. Johnston, W.G. Dougherty, Release of proteins and peptides from fusion proteins using a recombinant plant virus proteinase, Anal. Biochem. 216 (1994) 413–417.

[25] T.D. Parks, E.D. Howard, T.J. Wolpert, D.J. ARP, W.G. Dougherty, Expression and purification of a recombinant Tobacco Etch Virus NLa protease: biochemical analysis of full-length and a naturally occurring truncated protease form, Virology 210 (1995) 194–201.

[26] R.B. Kapust, J. Tozser, J.D. Fox, D.E. Anderson, S. Cherry, T.D. Copeland, D.S. Waugh, Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency, Protein Eng. 14 (2001) 993–1000.

[27] S. Nallamsetty, R.B. Kapust, J. Tozser, S. Cherry, J.E. Tropea, T.D. Copeland, D.S. Waugh, Efficient site-specific processing of fusion proteins by tobacco vein motting virus protease in vivo and in vitro, Protein Expr. Purif. 38 (2004) 108–115.

[28] S.Y. Kwon, Y.J. Choi, T.H. Kang, K.H. Lee, S.S. Cha, G.H. Kim, H.S. Lee, K.T. Kim, J.K. Kim, Highly efficient protein expression and Purification using bacterial hemoglobin fusion vector, Plasmid 53 (2005) 274–282.

[29] J.A. Garcia, S. Lain, Proteolytic activity of plasm Pox virus-tobacco etch virus chimeric NLa proteases, FEBS Lett. 281 (1991) 67–72.

[30] S. Urcuqui-Inchima, A.L. Haenni, F. Bernardi, Potyvirus proteins: a wealth of functions, Virus Res. 74 (2001) 157–175.

[31] J.L. Riechmann, S. Lain, J.A. Garcia, Highlights and prospects of potyvirus molecular biology, J. Gen. Virol. 73 (1992) 1–16.

[32] J.A. Garcia, M.T. Martin, M.T. Cervera, J.L. Riechmann, Proteolytic processing of the plasm Pox virus polyprotein by the Nla protease at a novel cleavage site, Virology 188 (1992) 697–703.

[33] H.Y. Yoon, D.C. Hwang, K.Y. Choi, B.D. Song, Proteolytic processing of oligopeptides containing the target sequences by the recombinant tobacco vein motting virus NLa proteinase, Mol. Cells 10 (2000) 213–219.
J.F. Bazan, R.J. Fletterick, Viral cysteine proteases are homologous to the trypsin-like family of serine proteases: structural and functional implications, Proc. Natl. Acad. Sci. USA 85 (1988) 7872–7876.

J.A. Garcia, J.L. Riechmann, S. Lain, Artificial cleavage site recognized by plum pox potyvirus protease in *Escherichia coli*, J. Virol. 63 (1989) 2457–2460.

J.A. Garcia, J.L. Riechmann, S. Lain, Proteolytic activity of the plum pox potyvirus Nla-like protein in *Escherichia coli*, Virology 170 (1989) 362–369.

R. Wen, S.C. Zhang, D. Michaud, H. Sanfacon, Inhibitory effects of cystatins on proteolytic activities of the Plum pox potyvirus cysteine proteinases, Virus Res. 105 (2004) 175–182.

E.E. Wyckoff, J.W. Hershey, E. Ehrenfeld, Eukaryotic initiation factor 3 is required for poliovirus 2A protease-induced cleavage of the p220 component of eukaryotic initiation factor 4F, Proc. Natl. Acad. Sci. USA 87 (1990) 9529–9533.

B.L. Scott, E. Racz, R.N. Lolley, N.G. Bazan, Developing rod photoreceptors from normal and mutant Rd mouse retinas: altered fatty acid composition early in development of the mutant, J. Neurosci. Res. 20 (1988) 202–211.

D.C. Hwang, D.H. Kim, J.S. Lee, B.H. Kang, J. Han, W. Kim, B.D. Song, K.Y. Choi, Characterization of active-site residues of the Nla protease from tobacco vein mottling virus, Mol. Cells 10 (2000) 505–511.

J.A. Garcia, M.T. Cervera, J.L. Riechmann, C. Lopez-Otin, Inhibitory effects of human cystatin C on plum pox potyvirus proteases, Plant Mol. Biol. 22 (1993) 697–701.

A.K. Mohanty, C.R. Simmons, M.C. Wiener, Inhibition of tobacco etch virus protease activity by detergents, Protein Expr. Purif. 27 (2003) 109–114.

R.B. Kapust, D.S. Waugh, *Escherichia coli* maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused, Protein Sci. 8 (1999) 1668–1674.

V.H. Donaldson, J. Kleniewski, The role of plasmin in kinin-release by preparations of human thrombin, Thromb Res. 16 (1979) 401–406.

S. Suzuki, N. Sakuragawa, A study on the properties of commercial thrombin preparations, Thromb Res. 53 (1989) 271–277.

R.D. Litwiller, R.J. Jenny, K.G. Mann, Identification and isolation of vitamin K-dependent proteins by HPLC, Anal. Biochem. 158 (1986) 355–360.

J.A. Garcia, J.L. Riechmann, M.T. Martin, S. Lain, Proteolytic activity of the plum pox potyvirus Nla-protein on excess of natural and artificial substrates in *Escherichia coli*, FEBS Lett. 257 (1989) 269–273.

J.A. Garcia, S. Lain, M.T. Cervera, J.L. Riechmann, M.T. Martin, Mutational analysis of plum pox potyvirus polyprotein processing by the Nla protease in *Escherichia coli*, J. Gen. Virol. 71 (Pt 12) (1990) 2773–2779.

A.S. Zhdanov, J. Phan, A.G. Evdokimov, J.E. Tropea, R.B. Kapust, M. Li, A. Wlodawer, D.S. Waugh, Tobacco etch virus proteinase: crystal structure of the active enzyme and its inactive mutant, Bioorg. Khim 29 (2003) 457–460.

R.J. Jenny, K.G. Mann, R.L. Lundblad, A critical review of the methods for cleavage of fusion proteins with thrombin and factor Xa, Protein Expr. Purif. 31 (2003) 1–11.

J.F. Marcos, R.N. Beachy, In vitro characterization of a cassette to accumulate multiple proteins through synthesis of a self-processing polypeptide, Plant Mol. Biol. 24 (1994) 495–503.

M.C. Hall, T.A. Kunkel, Purification of eucaryotic MutL homologs from *Saccharomyces cerevisiae* using self-cleaving, Protein Expr. Purif. 22 (2001) 25–30.

J.P. Shih, H.C. Wu, S.M. Hu, T.F. Wang, A.H. Wang, Self-cleavage of fusion protein in vivo using TEV protease to yield native protein, Protein Sci. 14 (2005) 936–941.

J. Perez-Martin, I. Cases, V. de Lorenzo, Design of a solubilization pathway for recombinant polypeptides in vivo through processing of a bi-protein with a viral protease, Protein Eng. 10 (1997) 725–730.